175 related articles for article (PubMed ID: 34152396)
1. Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma.
Spaan I; Timmerman LM; Kimman T; Slomp A; Cuenca M; van Nieuwenhuijzen N; Moesbergen LM; Minnema MC; Raymakers RA; Peperzak V
Blood Adv; 2021 Jun; 5(12):2593-2607. PubMed ID: 34152396
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.
Strömberg T; Dimberg A; Hammarberg A; Carlson K; Osterborg A; Nilsson K; Jernberg-Wiklund H
Blood; 2004 Apr; 103(8):3138-47. PubMed ID: 15070696
[TBL] [Abstract][Full Text] [Related]
4. Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells.
Teh CE; Gong JN; Segal D; Tan T; Vandenberg CJ; Fedele PL; Low MSY; Grigoriadis G; Harrison SJ; Strasser A; Roberts AW; Huang DCS; Nolan GP; Gray DHD; Ko ME
Cell Death Differ; 2020 Jul; 27(7):2217-2233. PubMed ID: 31988495
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of long noncoding RNA Sox2ot protects PC-12 cells from hydrogen peroxide-induced injury in spinal cord injury via regulating the miR-211-myeloid cell leukemia-1 isoform2 axis.
Yin D; Zheng X; Zhuang J; Wang L; Liu B; Chang Y
J Cell Biochem; 2018 Dec; 119(12):9675-9684. PubMed ID: 30145837
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
Wong KY; Chim CS
J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
[TBL] [Abstract][Full Text] [Related]
7. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Pei XY; Dai Y; Rahmani M; Li W; Dent P; Grant S
Clin Cancer Res; 2005 Jun; 11(12):4589-600. PubMed ID: 15958645
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
Slomp A; Moesbergen LM; Gong JN; Cuenca M; von dem Borne PA; Sonneveld P; Huang DCS; Minnema MC; Peperzak V
Blood Adv; 2019 Dec; 3(24):4202-4214. PubMed ID: 31856269
[TBL] [Abstract][Full Text] [Related]
9. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
Yan H; Frost P; Shi Y; Hoang B; Sharma S; Fisher M; Gera J; Lichtenstein A
Cancer Res; 2006 Feb; 66(4):2305-13. PubMed ID: 16489035
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
Voorhees PM; Chen Q; Small GW; Kuhn DJ; Hunsucker SA; Nemeth JA; Orlowski RZ
Br J Haematol; 2009 May; 145(4):481-90. PubMed ID: 19344406
[TBL] [Abstract][Full Text] [Related]
12. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
[TBL] [Abstract][Full Text] [Related]
13. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.
Pei XY; Dai Y; Felthousen J; Chen S; Takabatake Y; Zhou L; Youssefian LE; Sanderson MW; Bodie WW; Kramer LB; Orlowski RZ; Grant S
PLoS One; 2014; 9(3):e89064. PubMed ID: 24594907
[TBL] [Abstract][Full Text] [Related]
14. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
Yasui H; Hideshima T; Hamasaki M; Roccaro AM; Shiraishi N; Kumar S; Tassone P; Ishitsuka K; Raje N; Tai YT; Podar K; Chauhan D; Leoni LM; Kanekal S; Elliott G; Munshi NC; Anderson KC
Blood; 2005 Jul; 106(2):706-12. PubMed ID: 15802527
[TBL] [Abstract][Full Text] [Related]
15. Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by rapamycin in human myeloma cells.
López-Royuela N; Balsas P; Galán-Malo P; Anel A; Marzo I; Naval J
Biochim Biophys Acta; 2010 Feb; 1803(2):311-22. PubMed ID: 19914305
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
[TBL] [Abstract][Full Text] [Related]
17. Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.
Sriskandarajah P; De Haven Brandon A; MacLeod K; Carragher NO; Kirkin V; Kaiser M; Whittaker SR
BMC Cancer; 2020 Mar; 20(1):269. PubMed ID: 32228485
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Ramakrishnan VG; Miller KC; Macon EP; Kimlinger TK; Haug J; Kumar S; Gonsalves WI; Rajkumar SV; Kumar SK
Haematologica; 2019 Oct; 104(10):2061-2074. PubMed ID: 30846494
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.
Ponder KG; Matulis SM; Hitosugi S; Gupta VA; Sharp C; Burrows F; Nooka AK; Kaufman JL; Lonial S; Boise LH
Cancer Biol Ther; 2016 Jul; 17(7):769-77. PubMed ID: 27246906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
